In a reciprocal manner, EGFR inhibition is effective in most epithelial cancers with EGFR mutations, but molecular alterations of KRAS have been implicated in acquired resistance to anti-EGFR therapies in colon cancer patients22. Here, EGFR is linked to malignant colon neoplasm.